Aniko Szabo, PhD

Professor

Locations

Biostatistics

Contact Information

Education

PhD - Applied Statistics, University of Memphis, Memphis, TN, 1998
MS - Statistics, University of Memphis, Memphis, TN, 1997
MS - Mathematics, Eötvös University, Budapest, Hungary, 1994

Research Experience

Mathematical Modeling of Cancer Screening and Oncogenesis.

Leadership Positions

Director of the Biostatistics Consulting Center

Research Interests

Dr. Aniko Szabo is an Associate Professor and Director of the Biostatistics Consulting Service. Dr. Szabo's research interests are in statistical modeling of biomedical data. She has worked on analysis methods for PCR and microarray data, developing tree models of oncogenesis, nonparametric models of clustered discrete data, and population level models of the effect of screening on prostate cancer incidence. She collaborates with biomedical investigators across the entire spectrum of translational research from analyzing cellular assays, animal experiments, and observational studies in patients to designing prospective clinical trials and evaluation of policy impacts in national databases.

Curriculum Vitae

Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.

(Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplant. 2021 Apr 06 PMID: 33824440 04/08/2021
Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation.

(Bhasin B, Ber Ce P, Szabo A, Chhabra S, D'Souza A.) Am J Med Sci. 2021 Apr 02 PMID: 33812909 04/05/2021
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.

(Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E.) Cancer. 2021 Apr 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020
An integrative healthcare model with heartfulness meditation and care coordination improves outcomes in cyclic vomiting syndrome.

(Venkatesan T, Porcelli A, Matapurkar A, Suresh Kumar VC, Szabo A, Yin Z, Wieloch L.) Neurogastroenterol Motil. 2021 Mar 28:e14132 PMID: 33774892 SCOPUS ID: 2-s2.0-85103176132 03/29/2021
Risk factors for perioperative hypothermia and infectious outcomes in gastroschisis patients.

(Bence CM, Landisch RM, Wu R, Szabo A, McElhinney K, Austin MT, Fraser JD, St Peter SD, Joshi S, Lillegard JB, Tay S, Warner BW, Kim AG, Perrone EE, Leys CM, Kohler JE, Wagner AJ.) J Pediatr Surg. 2021 Mar 26 PMID: 33865604 SCOPUS ID: 2-s2.0-85104656858 04/19/2021
Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations.

(Chiu YE, Shmuylovich L, Kiguradze T, Anderson K, Sibbald C, Tollefson M, Kunzler E, Tom WL, Bond K, Ahmad RC, Garcia-Romero MT, Irfan M, Kollman K, Hunt R, Stein SL, Arkin L, Wong V, Pope E, Jacobe H, Brandling-Bennett HA, Cordoro KM, Bercovitch L, Rangel SM, Liu X, Szabo A, Paller AS.) J Am Acad Dermatol. 2021 Mar 06 PMID: 33689776 SCOPUS ID: 2-s2.0-85103699225 03/11/2021
Clinical characteristics of testicular extramedullary involvement in multiple myeloma.

(Mohan M, Yarlagadda N, Szabo A, Singh A, Pina Oviedo S, Schinke C.) Am J Hematol. 2021 03 01;96(3):E77-E81 PMID: 33338289 SCOPUS ID: 2-s2.0-85099245703 12/19/2020
Test of an organizational change model to reduce no-shows in dental care settings.

(Okunseri C, Boss D, Jacobson N, Wang MV, Szabo A, Okunseri E, Molfenter T.) J Public Health Dent. 2021 Feb 10 PMID: 33569828 02/12/2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

(Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR.) Transl Psychiatry. 2021 01 18;11(1):58 PMID: 33462203 PMCID: PMC7812704 SCOPUS ID: 2-s2.0-85100097244 01/20/2021
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma

(Nelson AA, Cronk RJ, Lemke EA, Szabo A, Khaki AR, Diamantopoulos LN, Grivas P, Nezami BG, MacLennan GT, Zhang T, Hoimes CJ.) Bladder Cancer. 2021;7(1):33-42 SCOPUS ID: 2-s2.0-85103035057 01/01/2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

(Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplantation. 2021 SCOPUS ID: 2-s2.0-85103674051 01/01/2021
Dental service utilization and immigrant family structure.

(Okunseri CE, Rota K, Okunseri E, Patel K, Garcia RI, Zheng C, Szabo A.) J Public Health Dent. 2020 Dec 01 PMID: 33258107 12/02/2020

Aniko Szabo, PhD

Aniko Szabo, PhD

Professor

Locations

Contact Information

Education

Research Experience

Leadership Positions

Research Interests

Publications